Compare CCLD & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCLD | MXCT |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | 3650 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 93.0M |
| IPO Year | N/A | 2021 |
| Metric | CCLD | MXCT |
|---|---|---|
| Price | $2.38 | $0.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | ★ 596.1K | 586.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | $11.49 | N/A |
| Revenue Next Year | $7.95 | $18.50 |
| P/E Ratio | $32.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.95 | $0.64 |
| 52 Week High | $4.01 | $2.40 |
| Indicator | CCLD | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 31.45 | 51.68 |
| Support Level | $2.22 | $0.77 |
| Resistance Level | $3.14 | $0.89 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 11.16 | 51.87 |
CareCloud Inc delivers flexible, tech-enabled solutions for healthcare providers of all sizes and multi-specialties across the U.S. It is a healthcare technology company offering cloud-based solutions that simplify clinical, administrative, and financial workflows for medical practices of all sizes. Its comprehensive suite includes Electronic Health Records (EHRs), Practice Management, Revenue Cycle Management (RCM), Medical Billing, Telehealth, and Patient Experience solutions. The group helps practices increase efficiency, improve patient care, and drive sustainable growth-all while ensuring HIPAA compliance and seamless integration. The operating segments of the group are Healthcare IT, which is the key revenue-generating segment, and Medical Practice Management.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.